[go: up one dir, main page]

MX2008011823A - Forma de dosificacion solida que contiene un agente activo de sabor encubierto. - Google Patents

Forma de dosificacion solida que contiene un agente activo de sabor encubierto.

Info

Publication number
MX2008011823A
MX2008011823A MX2008011823A MX2008011823A MX2008011823A MX 2008011823 A MX2008011823 A MX 2008011823A MX 2008011823 A MX2008011823 A MX 2008011823A MX 2008011823 A MX2008011823 A MX 2008011823A MX 2008011823 A MX2008011823 A MX 2008011823A
Authority
MX
Mexico
Prior art keywords
dosage form
solid dosage
active agent
flavor
covered
Prior art date
Application number
MX2008011823A
Other languages
English (en)
Inventor
Alexander Mark Schobel
Shyam Sundar Kumar Sarma Vangala
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2008011823A publication Critical patent/MX2008011823A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporciona una forma de dosificación sólida que contiene un agente activo de sabor encubierto. La forma de dosificación sólida puede ser proporcionada como una película soluble en agua que es desintegrable en la cavidad oral para liberar y distribuir el agente activo de sabor encubierto. La película desintegrable incluye al menos un polímero soluble en agua y un ketoprofeno activo de sabor encubierto. También se proporcionan métodos para preparar la forma de dosificación sólida y para usar la forma de dosificación sólida para administrar una dosificación efectiva de un agente activo, tal como ketoprofeno, en la cavidad oral para absorción.
MX2008011823A 2006-03-16 2007-03-15 Forma de dosificacion solida que contiene un agente activo de sabor encubierto. MX2008011823A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78318906P 2006-03-16 2006-03-16
PCT/US2007/006452 WO2007109057A2 (en) 2006-03-16 2007-03-15 Solid dosage form containing a taste masked active agent

Publications (1)

Publication Number Publication Date
MX2008011823A true MX2008011823A (es) 2008-10-31

Family

ID=38372464

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008011823A MX2008011823A (es) 2006-03-16 2007-03-15 Forma de dosificacion solida que contiene un agente activo de sabor encubierto.

Country Status (15)

Country Link
US (2) US8986735B2 (es)
EP (1) EP1998762B1 (es)
JP (1) JP5242543B2 (es)
CN (1) CN101404990B (es)
AT (1) ATE486593T1 (es)
AU (1) AU2007227614B2 (es)
BR (1) BRPI0709382A2 (es)
CA (1) CA2643944C (es)
DE (1) DE602007010254D1 (es)
ES (1) ES2355306T3 (es)
MX (1) MX2008011823A (es)
PL (1) PL1998762T3 (es)
PT (1) PT1998762E (es)
RU (1) RU2437657C2 (es)
WO (1) WO2007109057A2 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007227614B2 (en) * 2006-03-16 2011-01-06 Gsk Consumer Healthcare Sarl Solid dosage form containing a taste masked active agent
UY32836A (es) 2009-08-12 2011-03-31 Bayer Schering Pharma Ag Partículas estabilizadas que comprenden 5-metil-(6s)-tetrahidrofolato
WO2011020610A1 (en) 2009-08-19 2011-02-24 Bayer Schering Pharma Aktiengesellschaft Drug delivery systems (wafer) for pediatric use
CA2771403C (en) 2009-08-19 2015-02-24 Eisai R&D Management Co. Ltd. Quinoline derivative-containing pharmaceutical composition
JP6050564B2 (ja) * 2010-03-11 2016-12-21 テイカ製薬株式会社 フィルム状製剤
JP2012031164A (ja) * 2010-07-06 2012-02-16 Teika Seiyaku Kk フィルム状製剤
JP5853460B2 (ja) * 2010-07-30 2016-02-09 大正製薬株式会社 内服液剤
EP2663294B1 (en) 2011-01-11 2015-09-30 Capsugel Belgium NV New hard capsules comprising pullulan
CA2838589C (en) 2011-06-08 2019-08-20 Lts Lohmann Therapie-Systeme Ag Edible oral strip or wafer dosage form containing ion exchange resin for taste masking
KR101328350B1 (ko) 2012-02-28 2013-11-11 주식회사 서울제약 실데나필 또는 이의 약제학적으로 허용되는 염을 유효성분으로 함유하는 고미가 은폐된 약제학적 조성물
JP5941558B2 (ja) * 2012-02-28 2016-06-29 株式会社ソウル製薬Ｓｅｏｕｌ Ｐｈａｒｍａ． Ｃｏ．， Ｌｔｄ． シルデナフィルを有効成分として含有し、且つ、苦味の隠蔽された高含量速溶フィルム
JP2013231011A (ja) * 2012-05-01 2013-11-14 Sawai Pharmaceutical Co Ltd アトルバスタチン含有医薬組成物およびそれを用いた口腔内崩壊錠
MY189110A (en) * 2014-06-24 2022-01-26 Catherine LEE Fast acting orally disintegrating film
CN106659751B (zh) * 2014-07-17 2020-12-25 赫克萨尔股份公司 口腔可分散膜
CN104257637A (zh) * 2014-09-26 2015-01-07 天津市聚星康华医药科技有限公司 一种酮洛芬口腔速溶膜及其制备方法
US20180028662A1 (en) 2015-02-25 2018-02-01 Eisai R&D Management Co., Ltd. Method for Suppressing Bitterness of Quinoline Derivative
CN108135894B (zh) 2015-08-20 2021-02-19 卫材R&D管理有限公司 肿瘤治疗剂
WO2018129079A1 (en) * 2017-01-03 2018-07-12 Thermolife International, Llc Method of isolating theacrine and composition comprising theacrine
US20190336453A1 (en) * 2017-01-04 2019-11-07 BonAyu Lifesciences Private Limited Oral dispersible film composition
JP6581320B2 (ja) 2017-02-08 2019-09-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療用医薬組成物
AU2018253392B2 (en) 2017-04-14 2023-11-02 Capsugel Belgium Nv Process for making pullulan
AU2018251256B2 (en) 2017-04-14 2023-10-05 Capsugel Belgium Nv Pullulan capsules
RU2019134940A (ru) 2017-05-16 2021-06-16 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Лечение гепатоцеллюлярной карциномы
CN108113962B (zh) * 2018-02-23 2021-06-25 成都中医药大学 一种降低含有多酚的中药口服制剂涩味的方法
EP3670489A1 (en) 2018-12-21 2020-06-24 Dompé farmaceutici S.p.A. Co-crystal of ketoprofen, compositions comprising the same, process of producing the same, and uses thereof
EP3842408A1 (en) 2019-12-23 2021-06-30 Dompé farmaceutici S.p.A. Co-crystal of ketoprofen and its preparation, pharmaceutical compositions comprising the same and uses thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4145440A (en) 1977-08-18 1979-03-20 The Upjohn Company Liquid suspension of an aluminum salt of ibuprofen
US4361580A (en) 1980-06-20 1982-11-30 The Upjohn Manufacturing Company Aluminum ibuprofen pharmaceutical suspensions
GB8813682D0 (en) 1988-06-09 1988-07-13 Reckitt & Colmann Prod Ltd Pharmaceutical compositions
US5032384A (en) * 1989-01-27 1991-07-16 Block Drug Company, Inc. Compositions and method for the treatment of disease
US5416181A (en) 1989-02-10 1995-05-16 Penford Products Company Reinforced films made from water soluble polymers
CA2021548A1 (en) * 1989-09-01 1991-03-02 Ronald Nash Duvall Effervescent cold or sinus allergy medicine composition having reduced sodium content
US5262179A (en) 1989-09-13 1993-11-16 Nicholas Kiwi Pty Ltd. Non-effervescent ibuprofen compositions
DE4018247A1 (de) 1990-06-07 1991-12-12 Lohmann Therapie Syst Lts Herstellungsverfahren fuer schnellzerfallende folienfoermige darreichungsformen
US5024997A (en) 1990-06-22 1991-06-18 American Home Products Corporation Palatable ibuprofen solutions
JPH0541602A (ja) 1991-08-06 1993-02-19 Fujitsu General Ltd 円偏波及び直線偏波共用一次放射器
GB9207990D0 (en) 1992-04-10 1992-05-27 Smithkline Beecham Plc Pharmaceutical composition
TW271400B (es) * 1992-07-30 1996-03-01 Pfizer
GB9316580D0 (en) 1993-08-10 1993-09-29 Smithkline Beecham Plc Pharmaceutical composition
GB9318880D0 (en) 1993-09-11 1993-10-27 Smithkline Beecham Plc Pharmaceutical composition
IT1277741B1 (it) * 1995-12-28 1997-11-12 Dompe Spa Composizioni farmaceutiche parenterali contenenti sali di alchilammonio di acidi 2-arilpropionici
AUPN969796A0 (en) 1996-05-07 1996-05-30 F.H. Faulding & Co. Limited Taste masked liquid suspensions
US5800832A (en) 1996-10-18 1998-09-01 Virotex Corporation Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces
DE19646392A1 (de) 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht
NZ333474A (en) 1998-01-02 1999-06-29 Mcneil Ppc Inc A chewable tablet containing ibuprofen, fumaric acid and a non hydrocolloid binder e.g. a wax or a fat
JP3746167B2 (ja) * 1998-05-18 2006-02-15 武田薬品工業株式会社 医薬製剤
US6596298B2 (en) 1998-09-25 2003-07-22 Warner-Lambert Company Fast dissolving orally comsumable films
US20030206942A1 (en) * 1998-09-25 2003-11-06 Neema Kulkarni Fast dissolving orally consumable films containing an antitussive and a mucosa coating agent
WO2000057857A1 (en) * 1999-03-25 2000-10-05 Yuhan Corporation Rapidly disintegrable tablet for oral administration
US6090401A (en) 1999-03-31 2000-07-18 Mcneil-Ppc, Inc. Stable foam composition
US7067116B1 (en) 2000-03-23 2006-06-27 Warner-Lambert Company Llc Fast dissolving orally consumable solid film containing a taste masking agent and pharmaceutically active agent at weight ratio of 1:3 to 3:1
US6995190B2 (en) * 2001-03-09 2006-02-07 Veterinary Solutions Method and treatment with ketoprofen solution
US6656493B2 (en) 2001-07-30 2003-12-02 Wm. Wrigley Jr. Company Edible film formulations containing maltodextrin
US6419903B1 (en) 2001-08-20 2002-07-16 Colgate Palmolive Company Breath freshening film
DE10207394B4 (de) * 2002-02-21 2007-03-29 Lts Lohmann Therapie-Systeme Ag Geschmacksmaskierte oblatenförmige Arzneizubereitung
US20040043134A1 (en) * 2002-08-27 2004-03-04 Corriveau Christine Leclair Rolled edible thin film products and methods of making same
US7090859B2 (en) * 2002-12-13 2006-08-15 Ronald Thomas Haas Ketoprofen compositions and methods of making them
US20040208931A1 (en) * 2002-12-30 2004-10-21 Friend David R Fast dissolving films for oral administration of drugs
WO2005004989A2 (en) * 2003-07-01 2005-01-20 Todd Maibach Film comprising therapeutic agents
JP4563393B2 (ja) * 2003-10-24 2010-10-13 アドヒーシブズ・リサーチ・インコーポレイテッド 診断デバイス用崩壊性フィルム
US20060198885A1 (en) * 2005-02-22 2006-09-07 Sun Pharmaceutical Industries Ltd. Oral pharmaceutical composition
AU2007227614B2 (en) * 2006-03-16 2011-01-06 Gsk Consumer Healthcare Sarl Solid dosage form containing a taste masked active agent
WO2008112124A2 (en) * 2007-03-07 2008-09-18 Novartis Ag Orally administrable films

Also Published As

Publication number Publication date
PT1998762E (pt) 2010-11-30
RU2437657C2 (ru) 2011-12-27
JP2009530291A (ja) 2009-08-27
WO2007109057A2 (en) 2007-09-27
AU2007227614B2 (en) 2011-01-06
ATE486593T1 (de) 2010-11-15
CA2643944C (en) 2013-11-26
ES2355306T3 (es) 2011-03-24
DE602007010254D1 (de) 2010-12-16
JP5242543B2 (ja) 2013-07-24
US20070292515A1 (en) 2007-12-20
EP1998762A2 (en) 2008-12-10
US8986735B2 (en) 2015-03-24
BRPI0709382A2 (pt) 2011-07-12
AU2007227614A1 (en) 2007-09-27
EP1998762B1 (en) 2010-11-03
US20150157717A1 (en) 2015-06-11
WO2007109057A3 (en) 2007-12-06
CA2643944A1 (en) 2007-09-27
RU2008140383A (ru) 2010-04-27
PL1998762T3 (pl) 2011-04-29
CN101404990A (zh) 2009-04-08
CN101404990B (zh) 2012-04-25

Similar Documents

Publication Publication Date Title
MX2008011823A (es) Forma de dosificacion solida que contiene un agente activo de sabor encubierto.
WO2007095600A3 (en) Disintegrable oral films
AR078417A1 (es) Composiciones de pelicula sublingual y bucal
CL2013001136A1 (es) Un agente inhibitorio de la fosfodiesterasa 7 (pde7) para ser usado en el tratamiento o la reduccion de la posibilidad de una adiccion; y composicion farmaceutica, forma de dosificacion unitaria y kit farmaceutico que incluyen al inhibidor de fosfodiesterasa 7 (pde7) y un agente terapeutico adicional.
ECSP10010514A (es) Formulaciones mejoradas para ingredientes farmaceuticos activos de permeabilidad deficiente
CL2011001621A1 (es) Composicion farmaceutica oral de liberacion sostenida que comprende en una forma de dosificacion unitaria, una matriz hidrofilica, un opioide, una sal de un aine, y opcionalmente un surfactante aniónico; y uso para preparar medicamentos utiles en la prevencion, alivio o disminución del nivel del dolor y supresión de la tos.
EP2395834A4 (en) Sodium nitrite-containing pharmaceutical compositions
WO2008040534A3 (en) Non-mucoadhesive film dosage forms
CL2013000481A1 (es) Metodo y para mejorar la eficacia y/o reducir los efectos secundarios de una farmacoterapia administrada de forma suboptima que comprende la administracion de un hexitol sustituido; composicion farmaceutica; combinacion farmaceutica; uso para tratar enfermedades proliferativas.
PE20211069A1 (es) Composicion que comprende 5'-metilselenoadenosina, selenoadenosil-l-homocisteina y gama glutamil-metilselenocisteina
CL2012002115A1 (es) Una pastilla blanda que comprende nicotina, gelificante, platificante, edulcorante, agente liberador, conservante, saborizante, agua y es capaz de disolverse en la cavidad bucal en un periodo de 5 y 15 minutos; y proceso de preparacion.
WO2010062688A3 (en) Dosage form for insertion into the mouth
BRPI0822885A2 (pt) Implemento para cuidado oral, método para administrar um agente ativo, e, kit para cuidado oral
MX2012003204A (es) Forma de dosificacion solida oral que contiene nanoparticulas y proceso para su formulacion utilizando gelatina de pescado.
AR083208A1 (es) Uso de estearato de magnesio en formulaciones de polvo seco para inhalacion
CO6480985A2 (es) Formulaciones para el tratamiento del dolor tisular profundo
CL2008000610A1 (es) Composicion en forma de dosificacion transdermica o transmucosa que comprende una relacion en peso de buprenorfina a naloxona entre 2,1:1 y 8:1, util para el tratamiento del dolor.
CL2015000375A1 (es) Composicion farmaceutica en forma de microparticulas que comprende un nucleo inerte y al menos una primera capa de principio activo; proceso de formacion de microparticulas; combinacion farmaceutica; kit farmaceutico; uso para tratar y/o prevenir edemas, enfermedades cardiovasculares, diabetes, hipertension, entre otras.
NZ599265A (en) A skin external composition comprising a salt and sugar as active ingredients for preventing and treating vaginosis and the use thereof
CL2009001841A1 (es) Uso de una composición de liberación sostenida de 4-aminopiridina para preparar un medicamento útil para tratar esclerosis multiple en un sujeto.
CL2013001612A1 (es) Una composicion para el cuidado bucal que comprende una fase continuada comprendiendo agua o alcohol polihidrico o su mezcla; un agente de blanqueado de la superficie del diente, el cual es un pigmento anacarado, dispersado en la fase continuada, y una ayuda de depositacion para el agente de blanqueado, el cual es un polisacarido.
AR048050A1 (es) Formas de administracion masticables, no comprimidas, dosificadas individualmente
WO2008051527A3 (en) Sustained release of agents for localized pain management
DK1974721T3 (da) Injiceringsdygtig steril farmaceutisk sammensætning med natriumpiperacillin og natriumtazobactam som aktive stoffer
PE20130147A1 (es) Combinacion farmaceutica de teobromina y un agente antitusivo no opioide

Legal Events

Date Code Title Description
FG Grant or registration